| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DG Daniel Guy Ethos Financial Group LLC | 13,251 | $48 | - | -$48 | -100% |
| - Industry | - Sector | Mr. Seth M. Shaw CEO | OTCQB Exchange | 87669X205 CUSIP |
| US Country | - Employees | - Last Dividend | 24 Jun 2009 Last Split | - IPO Date |
Tauriga Sciences, Inc. is a diversified company that focuses on the production and sale of cannabidiol (CBD) infused products, alongside the development of wellness and health products. Founded in 2001 and based in Wappingers Falls, New York, the company has expanded its product line to include a range of CBD-based items, catering to various customer needs. Tauriga is also engaged in a collaboration with Aegea Biotechnologies, Inc. to develop a rapid test for COVID-19, showcasing its versatility and commitment to contributing to global health solutions.
A line of cannabidiol infused chewing gum, providing customers with a discreet and convenient way to consume CBD.
Developed to help alleviate symptoms of nausea, these products blend CBD's natural benefits with other effective ingredients.
A collection of various CBD products, offering customers a chance to try a range of items and find their favorites.
These supplements provide a healthful addition to daily nutrition, made with non-GMO ingredients and infused with CBD.
Offering a luxurious bathing experience, these bath bombs combine aromatherapy with the relaxing properties of CBD.
The company markets its products through multiple channels, including e-commerce platforms, distributors, and wholesale avenues, ensuring wide accessibility and convenience for consumers. The collaboration with Aegea Biotechnologies, Inc. highlights Tauriga's involvement in health technology, specifically in addressing the global need for rapid COVID-19 testing solutions.